OLK NASDAQ
Olink Holding AB (publ)
1W: +2.1%
1M: +6.7%
3M: +12.2%
1Y: +44.4%
3Y: -21.5%
$26.08
Last traded 2024-07-09 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#26
of 92
Medical - Diagnostics & Research
Technical Signal Map
1 Bullish
2 Neutral
5 Bearish
OLK
$3.2B
Olink Holding AB (publ)
N/A
0
VIMIAN.ST
$19B
Vimian Group AB (publ)
BULLISH
+58
DVYSR.ST
$850M
Devyser Diagnostics AB (publ)
NEUTRAL
+1
IDLDX.ST
$80M
IDL Diagnostics AB (publ)
BEARISH
-35
SPERM.ST
$30M
Spermosens AB
BEARISH
-41
PROGEN.ST
—
Prostatype Genomics AB (publ)
BEARISH
-91
SENZA.ST
$150M
SenzaGen AB
BEARISH
-100
IMMNOV.ST
$30M
Immunovia AB
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| OLK Olink Holding AB (publ) | $3.2B | -100.3 | -7.0 | -12.3 | -55.9 | 18.5 | 1 | N/A | 44.4 |
| VIMIAN.ST Vimian Group AB (publ) | $19B | 44.9 | 5.2 | 6.4 | 6.9 | 11.1 | 6 | BULLISH | 7.5 |
| DVYSR.ST Devyser Diagnostics AB (publ) | $850M | 59.6 | 4.3 | 4.5 | 2.7 | 6.5 | 7 | NEUTRAL | -62.8 |
| IDLDX.ST IDL Diagnostics AB (publ) | $80M | 5.6 | -9.9 | -9.4 | -7.4 | — | 2 | BEARISH | -21.3 |
| SPERM.ST Spermosens AB | $30M | -2.2 | -34.2 | -28.6 | — | — | 4 | BEARISH | 13.5 |
| PROGEN.ST Prostatype Genomics AB (publ) | — | -0.2 | -206.1 | -496.0 | -2600.6 | -52.5 | 3 | BEARISH | -86.5 |
| SENZA.ST SenzaGen AB | $150M | -13.0 | -12.8 | -13.2 | -14.5 | 9.3 | 4 | BEARISH | -27.6 |
| IMMNOV.ST Immunovia AB | $30M | -0.5 | -427.0 | 816.7 | -5991.9 | 31.7 | 3 | BEARISH | -90.7 |
| OLK Olink Holding AB (publ) | $3.2B | -100.3 | -7.0 | -12.3 | -55.9 | 18.5 | 1 | N/A | 44.4 |
| VIMIAN.ST Vimian Group AB (publ) | $19B | 44.9 | 5.2 | 6.4 | 6.9 | 11.1 | 6 | BULLISH | 7.5 |
| DVYSR.ST Devyser Diagnostics AB (publ) | $850M | 59.6 | 4.3 | 4.5 | 2.7 | 6.5 | 7 | NEUTRAL | -62.8 |
| IDLDX.ST IDL Diagnostics AB (publ) | $80M | 5.6 | -9.9 | -9.4 | -7.4 | — | 2 | BEARISH | -21.3 |
| SPERM.ST Spermosens AB | $30M | -2.2 | -34.2 | -28.6 | — | — | 4 | BEARISH | 13.5 |
| PROGEN.ST Prostatype Genomics AB (publ) | — | -0.2 | -206.1 | -496.0 | -2600.6 | -52.5 | 3 | BEARISH | -86.5 |
| SENZA.ST SenzaGen AB | $150M | -13.0 | -12.8 | -13.2 | -14.5 | 9.3 | 4 | BEARISH | -27.6 |
| IMMNOV.ST Immunovia AB | $30M | -0.5 | -427.0 | 816.7 | -5991.9 | 31.7 | 3 | BEARISH | -90.7 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
OLK vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F